

December. 19 2023 Sysmex Corporation

[Overview presentation]

## VWF:RCo/VWF:Ag for diagnosis of acquired von Willebrand syndrome caused by aortic stenosis

Authors	Noriyuki Okubo, $PhD^1$ , Shingo Sugawara, $BS^1$ , Tohru Fujiwara, MD, $PhD^{1,2}$ , Ko
	Sakatsume, MD, PhD $^{3,4}$ , Tsuyoshi Doman, MD $^3$ , Mihoko Yamashita, BS $^3$ , Kota
	Goto, $MS^3$ , Masaki Tateishi, $MS^3$ , Misako Suzuki, $MS^3$ , Ryutaro Shirakawa,
	$PhD^3$ , Yuka Eura, $PhD^5$ , Koichi Kokame, $PhD^5$ , Masaki Hayakawa, MD, $PhD^6$ ,
	Masanori Matsumoto, MD, PhD <sup>6</sup> , Yasunori Kawate, MS <sup>7</sup> , Mizuki Miura, MD,
	PhD <sup>6</sup> , Hiroshi Takiguchi, MD <sup>8</sup> , Yoshimatsu Soga, MD, PhD <sup>8</sup> , Shinichi Shirai,
	$MD^8$ , Kenji Ando, $MD^8$ , Yoshio Arai, $MD^9$ , Takaharu Nakayoshi, MD, $PhD^{10}$ ,
	Yoshihiro Fukumoto, MD, PhD <sup>10</sup> , Hiroyuki Takahama, MD, PhD <sup>11,12,</sup> Satoshi
	Yasuda, MD, PhD <sup>11,12</sup> , Toshihiro Tamura, MD, PhD <sup>13</sup> , Shin Watanabe, MD,
	PhD <sup>14</sup> , Takeshi Kimura, MD, PhD <sup>14</sup> , Nobuhiro Yaoita, MD, PhD <sup>12</sup> , Hiroaki
	Shimokawa, MD, $PhD^{12}$ , Yoshikatsu Saiki, MD, $PhD^4$ , Koichi Kaikita, MD,
	PhD <sup>15</sup> , Kenichi Tsujita, MD, PhD <sup>15</sup> , Shinji Yoshii, MD, PhD <sup>16</sup> , Hiroshi Nakase,
	MD, PhD <sup>16</sup> , Shin-ichi Fujimaki, PhD <sup>1</sup> , Hisanori Horiuchi, MD, PhD <sup>3</sup>
	<sup>1</sup> Department of Clinical Laboratory Medicine, Tohoku University Hospital,
	Sendai, Japan
	<sup>2</sup> Department of Hematology, Tohoku University Graduate School of Medicine,
	Sendai, Japan
	<sup>3</sup> Department of Molecular and Cellular Biology, Institute of Development, Aging
	and Cancer, Tohoku University Graduate School of Medicine, Sendai, Japan
	<sup>4</sup> Division of Cardiovascular Surgery, Tohoku University Graduate School of
	Medicine, Sendai, Japan
	<sup>5</sup> Department of Molecular Pathogenesis, National Cerebral and Cardiovascular
	Center, Suita, Japan
	$^{6}\mbox{Department}$ of Blood Transfusion Medicine, Nara Medical University, Kashihara,
	Japan
	<sup>7</sup> Medical Affairs 2, Medical & Scientific Affairs, Sysmex Corporation, Kobe, Japan
	<sup>8</sup> Department of Cardiology, Kokura Memorial Hospital, Kokura-kitaku,

Sysmex Corporation



	Kitakvushu, Japan
	<sup>9</sup> Department of Cardiovascular Surgery, Kokura Memorial Hospital, Kokura-
	kitaku. Kitakvushu. Japan
	<sup>10</sup> Division of Cardiovascular Medicine. Department of Internal Medicine. Kurume
	University School of Medicine. Kurume, Japan
	<sup>11</sup> Cardiovascular Department, National Cerebral and Cardiovascular Center.
	Suita, Japan
	<sup>12</sup> Department of Cardiovascular Medicine, Tohoku University Graduate School
	of Medicine, Sendai, Japan
	<sup>13</sup> Department of Cardiology, Tenri Hospital, Tenri, Japan
	<sup>14</sup> Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto
	University, Kyoto, Japan
	<sup>15</sup> Department of Cardiovascular Medicine, Graduate School of Medical
	Sciences, Center for Metabolic Regulation of Healthy Aging, Kumamoto
	University, Kumamoto, Japan
	<sup>16</sup> Department of Gastroenterology and Hepatology, Sapporo Medical University
	School of Medicine, Sapporo, Japan
Overview	Background
presentation	Severe aortic stenosis (AS) causes acquired von Willebrand syndrome (AVWS)
	by the excessive shear-stress-dependent cleavage of high molecular weight
	multimers of von Willebrand factor (VWF). While the current standard diagnostic
	method is so-called VWF multimer analysis that is western blotting under non-
	reducing conditions, it remains unclear whether a ratio of VWF ristocetin co-
	factor activity (VWF:RCo) to VWF antigen levels (VWF:Ag) of <0.7, which can be
	measured with an automated coagulation analyzer in clinical laboratories and is
	used for the diagnosis of hereditary von Willebrand disease, is useful for the
	diagnosis of AS-induced AVWS.
	Methods
	VWF:RCo and VWF:Ag were evaluated with the VWF large multimer index as a
	reference, which represents the percentage of a patient's VWF high molecular
	weight multimer ratio to that of standard plasma in the VWF multimer analysis.
	Results
	We analyzed 382 patients with AS having trans-aortic valve maximal pressure
	VWF:RCo and VWF:Ag were evaluated with the VWF large multimer index as a reference, which represents the percentage of a patient's VWF high molecular weight multimer ratio to that of standard plasma in the VWF multimer analysis. <b>Results</b>
	We analyzed 382 patients with AS having trans-aortic valve maximal pressure



	gradients over 30 mmHg, 27 patients with peripheral artery disease (PAD), and
	46 control patients free of cardiovascular disease with osteoarthritis, diabetes
	and so on. We assumed a large multimer index of <80% as loss of VWF large
	multimers since 59.0% of severe AS patients had the indices of <80%, while no
	control or PAD patients, except for two patients, exhibited the indices of <80%.
	The VWF:RCo/VWF:Ag ratios, measured by an automated blood coagulation
	analyzer, were correlated with the indices (rs=0.470, p<0.001). When the ratio
	<0.7 was used as a cut-off point, the sensitivity and specificity to VWF large
	multimer indices of <80% were 0.437 and 0.826, respectively.
	Conclusion
	VWF:RCo/VWF:Ag ratios <0.7 may indicate loss of VWF large multimers with
	high specificity, but low sensitivity. VWF:RCo/VWF:Ag ratios in AS patients with
	the ratio <0.7 may be useful for monitoring loss of VWF large multimers during
	their clinical courses.
	Keywords
	aortic stenosis acquired ,von Willebrand syndrome, VWF large multimer index,
	VWF ristocetin co-factor activity, VWF:RCo/VWF:Ag
Journal	"rpth": Research and Practice in Thrombosis and Haemostasis
	https://doi.org/10.1016/j.rpth.2023.102284